Literature DB >> 19994911

Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics.

Guro F Giskeødegård1, Maria T Grinde, Beathe Sitter, David E Axelson, Steinar Lundgren, Hans E Fjøsne, Steinar Dahl, Ingrid S Gribbestad, Tone F Bathen.   

Abstract

Axillary lymph node status together with estrogen and progesterone receptor status are important prognostic factors in breast cancer. In this study, the potential of using MR metabolomics for prediction of these prognostic factors was evaluated. Biopsies from breast cancer patients (n = 160) were excised during surgery and analyzed by high resolution magic angle spinning MR spectroscopy (HR MAS MRS). The spectral data were preprocessed and variable stability (VAST) scaled, and training and test sets were generated using the Kennard-Stone and SPXY sample selection algorithms. The data were analyzed by partial least-squares discriminant analysis (PLS-DA), probabilistic neural networks (PNNs) and Bayesian belief networks (BBNs), and blind samples (n = 50) were predicted for verification. Estrogen and progesterone receptor status was successfully predicted from the MR spectra, and were best predicted by PLS-DA with a correct classification of 44 of 50 and 39 of 50 samples, respectively. Lymph node status was best predicted by BBN with 34 of 50 samples correctly classified, indicating a relationship between metabolic profile and lymph node status. Thus, MR profiles contain prognostic information that may be of benefit in treatment planning, and MR metabolomics may become an important tool for diagnosis of breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19994911     DOI: 10.1021/pr9008783

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  59 in total

Review 1.  Triple-negative breast cancer: present challenges and new perspectives.

Authors:  Franca Podo; Lutgarde M C Buydens; Hadassa Degani; Riet Hilhorst; Edda Klipp; Ingrid S Gribbestad; Sabine Van Huffel; Hanneke W M van Laarhoven; Jan Luts; Daniel Monleon; Geert J Postma; Nicole Schneiderhan-Marra; Filippo Santoro; Hans Wouters; Hege G Russnes; Therese Sørlie; Elda Tagliabue; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

2.  Simultaneous analysis of plasma and CSF by NMR and hierarchical models fusion.

Authors:  Agnieszka Smolinska; Joram M Posma; Lionel Blanchet; Kirsten A M Ampt; Amos Attali; Tinka Tuinstra; Theo Luider; Marek Doskocz; Paul J Michiels; Frederic C Girard; Lutgarde M C Buydens; Sybren S Wijmenga
Journal:  Anal Bioanal Chem       Date:  2012-03-07       Impact factor: 4.142

Review 3.  Metabolomic profiling of hormone-dependent cancers: a bird's eye view.

Authors:  Stacy M Lloyd; James Arnold; Arun Sreekumar
Journal:  Trends Endocrinol Metab       Date:  2015-08-01       Impact factor: 12.015

4.  Targeting choline phospholipid metabolism: GDPD5 and GDPD6 silencing decrease breast cancer cell proliferation, migration, and invasion.

Authors:  Maria Dung Cao; Menglin Cheng; Asif Rizwan; Lu Jiang; Balaji Krishnamachary; Zaver M Bhujwalla; Tone F Bathen; Kristine Glunde
Journal:  NMR Biomed       Date:  2016-06-30       Impact factor: 4.044

5.  Glycerophosphocholine (GPC) is a poorly understood biomarker in breast cancer.

Authors:  Siver Andreas Moestue; Guro F Giskeødegård; Maria D Cao; Tone F Bathen; Ingrid S Gribbestad
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-31       Impact factor: 11.205

Review 6.  Breast Cancer Metabolism.

Authors:  Jessica Tan; Anne Le
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

7.  Clinical applications of breast cancer metabolomics using high-resolution magic angle spinning proton magnetic resonance spectroscopy (HRMAS 1H MRS): systematic scoping review.

Authors:  Almir G V Bitencourt; Johanna Goldberg; Katja Pinker; Sunitha B Thakur
Journal:  Metabolomics       Date:  2019-11-06       Impact factor: 4.290

8.  A distinct metabolic signature of human colorectal cancer with prognostic potential.

Authors:  Yunping Qiu; Guoxiang Cai; Bingsen Zhou; Dan Li; Aihua Zhao; Guoxiang Xie; Houkai Li; Sanjun Cai; Dong Xie; Changzhi Huang; Weiting Ge; Zhanxiang Zhou; Lisa X Xu; Weiping Jia; Shu Zheng; Yun Yen; Wei Jia
Journal:  Clin Cancer Res       Date:  2014-02-13       Impact factor: 12.531

9.  Plasma metabolomic profiles in breast cancer patients and healthy controls: by race and tumor receptor subtypes.

Authors:  Jie Shen; Li Yan; Song Liu; Christine B Ambrosone; Hua Zhao
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

10.  Biomarker Discovery and Translation in Metabolomics.

Authors:  G A Nagana Gowda; D Raftery
Journal:  Curr Metabolomics       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.